Do not treat a new approval headline as a complete account of the evidence. This short critical appraisal episode clarifies what a one-trial FDA default means, what it does not mean, and why that distinction matters when new therapies or devices are discussed.

The action here is not to ask whether AI exists, but how it is constrained. This episode is useful because it shows a safer model: institution-only protocols, source-cited answers, after-hours demand, and clinical questions that centre on seizure care, dosing, and brain death workflows.

The pitfall is calling failed treatment or missed review simple non-adherence. This is worth hearing for a practical framework that links housing, education, disability, and structural factors to whether neurological medication plans and follow-up can realistically succeed.

The reason not to reassure yourself is that a technically sound neurology plan can still fail when medication cost or food insecurity blocks access. This listen is worth opening for one practical change: ask directly about social barriers when seizures worsen or follow-up stops making sense.

Neurological complications are common enough to belong in routine procedural risk discussion, not as an afterthought. Make brain health counselling explicit, include family members, and do not assume patients understand neurological risk unless you have stated it clearly.

A normal neurological examination does not exclude meaningful morbidity after paediatric Ebola virus disease. Ask directly about limb weakness, faecal incontinence, mobility, vision and understanding speech, and use disability or executive function assessment because important long-term deficits may sit outside a standard examination.

A normal basic micronutrient screen does not exclude deficiency when the neurological phenotype is strong. In suspected functional malabsorption, start with iron indices, ferritin, vitamin D and B12, then add copper for myelopathy or sensory ataxia, thiamine for encephalopathy, and vitamin E when fat malabsorption dominates.

Chronic wasting disease counselling should be precautionary, not falsely reassuring. No confirmed human cases are demonstrated, but patients who hunt or process venison should be advised to test harvested animals where available and avoid meat or high-risk tissues from ill or positive cervids.

Hearing aid counselling in older adults should stay precise: the reported association is a possible reduction in dementia risk over seven years, not prevention. The revision point is to link hearing impairment management with cognition while avoiding claims that overstate the evidence.

Emerging migraine therapy is moving beyond CGRP, but trial signals still need disciplined interpretation. A useful bedside lesson is to document cranial autonomic symptoms and prior CGRP response carefully, because new peptide targets may help selected patients without yet replacing established treatments.